Intraocular Pressure Lowering Effect of Single Dose Timolol, Brimonidine and Latanoprost on Different Ages of Normotensive Volunteers
[1]
Hulya Gungel, Istanbul Training and Research Hospital, Istanbul, Turkey.
[2]
Cigdem Altan, Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
[3]
Isilay Kavadarlı, Sıslı Etfal Training and Research Hospital, Istanbul, Turkey.
[4]
Isil Pasaoglu, Beyoglu Eye Training and Research Hospital, Istanbul, Turkey.
Purpose: The aim of the study is to evaluate the difference between intraocular pressure (IOP) peak lowering effect of single dose topical timolol maleat, latanoprost and brimonidine tartarate on healthy people with different age groups. Methods: Eighty-nine eyes of 89 healthy volunteers were included. The patients younger than 51 years old were classified as group I and older than 64 years old were classified as group II. The patients were instilled a single drop of timolol maleat, brimonidine tartrate and latanoprost randomly. After evaluation for one drug a washout period of 1 week was allowed before second drug was evaluated. After baseline measurements, IOP measurements were repeated 2 hours after instillation of timolol and brimonidine drops and 12 hours after latanoprost drop. Results: A single drop of each three drugs were found to be effective in IOP-lowering both in two groups. There were no statistically significant difference in IOP change between three drugs in group I, whereas there were statistically significant difference in group II. The differences between the effects of both timolol and brimonidine on two groups were statistically insignificant. The IOP reducing effect of latanoprost was 3,5±2,0 mmHg in group I and 2,5±2,4 mmHg in group II (p=0.007). There was a negative correlation between age and IOP reduction in latanoprost group (p=0,002), but no correlation was found in other two drugs. Conclusion: Single doses of timolol, brimonidine and latanoprost have similar IOP-lowering effects in younger subjects. Timolol and brimonidine seemed to be more effective than latanoprost in reducing IOP in older cases.
Timolol, Brimonidine, Latanoprost, IOP-Lowering Effect, Age, Single Dose
[1]
Maeda-Chubachi T, Chi-Burris K, Simons BD, et al. Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study. Ophthalmology 2011;118(10):2014-21
[2]
Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand. 2001;79(6):567-71
[3]
Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006; 124(9):1230-8.
[4]
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009; 116(7):1243-9.
[5]
Camras CB, Hedman K; US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003; 12(6):466-9.
[6]
Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol 2004;49 Suppl 1:19-25
[7]
Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47 Suppl 1:77-89.
[8]
Gupta SK, Agarwal R, Galpalli ND, Srivastava S, Agrawal SS, Saxena R. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find Exp Clin Pharmacol 2007;29(10):665-71
[9]
Artunay O, Yuzbasioglu E, Unal M, Rasier R, Sengul A, Bahcecioglu H. Bimatoprost 0.03% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Spike Following Neodymium:Yttrium–Aluminum–Garnet Laser Posterior Capsulotomy. J Ocul Pharmacol Ther 2010;26(5):513-7
[10]
Unal M, Yucel I. Effect of Bimatoprost on intraocular pressure after cataract surgery. Can J Ophthalmol 2008; 43:712-6.
[11]
Chen TC, Ang RT, Grosskreutz CL, Pasquale LR, Fan JT. Brimonidine 0.2% versus Apraclonidine 0.5% for Prevention of Intraocular Pressure Elevations after Anterior Segment Laser Surgery. Ophthalmology 2001;108:1033–8
[12]
Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open angle glaucoma and ocular hypertension. Drugs&Aging 1998; 12(3): 226-41
[13]
Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment. J Glaucoma. 1997; 6(4): 250-8. Review.
[14]
Hellberg M, McLaughlin M, Sharif N, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol 2002; 47(Suppl 1):13-33.
[15]
Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother 2002; 36:504-11.
[16]
Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 2007; 114:1039-45.
[17]
Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging 2007; 24:509-28.
[18]
Orengo-Nania S, Landry T, Von Tress M, Silver LH, Weiner A, Davis AA. The Travoprost Study Group. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001; 132:860-8.
[19]
Schachtschabel U, Lindsey JD, Weuireb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opinion in Ophthalmol 2000; 11:112-15.
[20]
Marchini G, Chilott G, Banadiniani M, Babighian S. Effects of 0,005% Latanaprost on ocular anterior structures and ciliary body thichness. J Glaucoma 2003; 12:295-300.
[21]
Shields M.B. Textbook of Glaucoma. Baltımore, Williams and Wilkins, 1992: 431-45.
[22]
Kaufman PL, Mittag TW. Medical therapy of glaucoma. In: Kaufman PL, Mittag TW editors. Glaucoma. London: Mooby-Yearbook; 1994:9.7-9.30.
[23]
Mittag TW. Adrenergic and dopaminergic drugs in glaucoma. In: Rich R, Shields MB, Krupin T, editors. The Glaucoma, St Louis Mooby Year book 1996:1409-24.
[24]
Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978;96:2045-8
[25]
Gieser SC, Juzych M, Robin AL, Schwartz GF. Clinical Pharmacology of adrenergic drugs. In: Ritch R, Shields MB, Krupin T, editors. The Glaucoma St. Louis Mooby Yearbook 1996:1425-48.
[26]
İnan UU, Ermis SS, Orman A, et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J Ocul Pharmacol Ther 2004; 20:293-306.
[27]
Noecker RJ. Brimonidine 2% as a replacement for beta blockers in geriatric patients with glaucoma. Adv Ther 2002; 19:91-7.
[28]
Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on cilliary smooth muscle extracellular matrix metabolism: Implication for uveoscleral outflow. Surv Ophthalmol 1997;41(Suppl):53-9
[29]
Hedner J, Everts B, Möller CS. Latanoprost and respiratory function in asthmatic patients. Arch Ophthalmol 1999; 117:1305-9.
[30]
Vuori ML, Melkkila TM, Kaila T, Sari KM. Plasma and aqueous humour concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol 1993; 71:201-6.
[31]
Kiuchi Y, Takamatsu M, Mishima HK. PhXA41 a prostaglandin F2 analogue reduces the intraocular pressure in human volunteers during day and night. Invest Ophthalmol Vis Sci 1994; 35(Suppl):2178-84
[32]
Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2002; 18:287-91.
[33]
Bayer A, Henderer JD, Kwak T, Myers J, Fontanarosa J, Spaeth GL. Clinical predictors of latanoprost treatment effect. J Glaucoma 2005; 14:260-3.
[34]
Tamada Y, Taniguchi T, Murase H, Yamamoto T, Kitazawa Y. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 2001;17(1):19-25.
